Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 13/20 | 0.49 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4239283 | 0.84 | SLC6A9 (0.50) | SLC6A9SLC6A5 | |
| SCHEMBL4241807 | 0.84 | SLC6A9 (0.50) | SLC6A9SLC6A5 | |
| SCHEMBL4249594 | 0.84 | SLC6A9 (0.50) | SLC6A9SLC6A5 | |
| SCHEMBL4241759 | 0.76 | SLC6A9 (0.36) | SLC6A9SLC6A5CYP2C9 | |
| SCHEMBL4238321 | 0.76 | SLC6A9 (0.36) | SLC6A9SLC6A5CYP2C9 | |
| SCHEMBL4243958 | 0.75 | OXTR (0.34) | CYP2C9 | |
| SCHEMBL3708435 | 0.72 | SLC6A9 (0.76) | SLC6A9SLC6A5 | |
| SCHEMBL2124780 | 0.71 | SLC6A9 (0.43) | SLC6A9SLC6A5CYP2D6LMNACYP2C9 | |
| SCHEMBL2605333 | 0.71 | SLC6A9 (0.62) | SLC6A9SLC6A5 | |
| SCHEMBL2605325 | 0.71 | SLC6A9 (0.62) | SLC6A9SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120094995-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094995-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE COMPOUNDS AND USES THEREOF | SLC1A2, B4GALT1, SLC6A1 | SLC6A9 50/4885SLC6A5 33/4885CYP2D6 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.